News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Pfizer to withdraw Bextra from US, EU and Canadian markets


Posted on: 04/08/2005

Pfizer to withdraw Bextra from US, EU and Canadian markets

The FDA has asked Pfizer to withdraw its COX-2 drug, Bextra, from the US market "because its overall risk versus benefit profile is unfavourable." The agency also requested that labels for Celebrex, and all other prescription NSAIDS, carry a boxed warning highlighting the potential for cardiovascular and gastrointestinal risks. Additionally, Pfizer will suspend sales of Bextra in the EU and Canada, at the request of their respective regulators.

Source: First Word [4/8/05]


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740